Cardio Diagnostics Holdings, Inc. (CDIO)
Nasdaq · Healthcare · Biotechnology
$2.06+5.10%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $6.1M
- 52-week range
- $0.97 – $7.91
- 52-week change
- −55.40%
- EPS (trailing)
- −$2.91
- Next earnings
- Nov 6, 2026
Fiscal year to Dec 2025
- Revenue
- $15K (−57.51%)
- Net income
- −$6.5M
- Operating margin
- −43737.6%
- Diluted EPS
- −$3.71
- Free cash flow
- −$5.9M
From the company’s annual report on SEC EDGAR.
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Headquarters: Chicago, United States · 15 employees · cdio.ai